Using 99mTc-CNDG for diagnosing malignant tumors
A Prospective Study to Explore the Performance and Efficacy of 99mTc-CNDG Injection in Malignant Tumors
NA · Peking Union Medical College Hospital · NCT06030817
This study is testing a new imaging agent called 99mTc-CNDG to see if it can help doctors better diagnose malignant tumors in patients scheduled for surgery, while also being more affordable than the current option.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06030817 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a new SPECT imaging agent, 99mTc-CNDG, for diagnosing malignant tumors. Unlike the commonly used 18F-FDG, which is costly and requires specialized production, 99mTc-CNDG aims to provide a more accessible and cost-effective alternative. The study involves patients with various types of malignant tumors who are scheduled for surgical procedures, allowing for a direct comparison of imaging results. The goal is to improve diagnostic capabilities while reducing costs associated with tumor imaging.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-70 diagnosed with specific malignant tumors and scheduled for surgical resection or biopsy.
Not a fit: Patients who have undergone pre-treatment such as chemotherapy or targeted therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly lower the costs of tumor imaging and improve accessibility for patients.
How similar studies have performed: While SPECT imaging is established, the specific use of 99mTc-CNDG as a novel agent is relatively untested, making this approach innovative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-70 years old * Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, or other malignant tumors through imaging techniques such as MRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy * Solid tumor sizes greater than 2cm * Voluntarily agree to participate and sign an informed consent form * Can provide complete surgical records, pathological results, control data, and clinical follow-up results Exclusion Criteria: * Pre-treatment such as chemotherapy and targeted therapy has been administered * Pregnancy and breastfeeding * Claustrophobia * The condition is severe and difficult to cooperate with * Unable to obtain relevant control imaging data and clinical information
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (RECRUITING)
Study contacts
- Principal investigator: Hongli Jing — Peking Union Medical College Hospital
- Study coordinator: Hongli Jing
- Email: annsmile1976@sina.com
- Phone: +86-18600586399
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Tumor